Deferoxamine Mesylate
Phase 3Small molecule
Deferoxamine Mesylate is one of 98 small molecule programs targeting Stroke. It is currently in Phase 3.
4
Indications
4
Total Trials
2
Active Trials
97
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Deferoxamine Mesylate
TThe George Institute
Phase 3
Activase
RochePreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Pradaxa
Boehringer IngelheimPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Zantac 150
CChattem
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Anticoagulants
SanofiPreclinical
Botulinum Toxin a
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intracerebral Hemorrhage2 trials
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
Completed·—·Phase 2·NCT02175225·294 enrolled
Hemorrhage1 trial
Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage
Completed·—·Phase 1·NCT00598572·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Deferoxamine Mesylate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TThe George Institute